Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 199.20

+0.1%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: chirodoc who wrote (10970)	11/11/1997 5:35:00 AM
From: Henry Niman	Read Replies (1) of 32384

chirodoc, Pramlintide is not really stiff competition for Targretin and other rexinoids. So far it hasn't been showed to significantly help type II for extended time periods, although the lack of proof may be due to the clinical trial design. However, even if it does, most diabetics would rather treat the cause than the result of their disease. Pramlimtide in many respects is like a weaker version of insulin. Such injectables will eventually become obsolete and markets will shrink, not grow, which is one of the reasons LLY signed their deal with LGND (and I wouldn't be surprised if JNJ were talking to AGN).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next